Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Chronic lymphocytic leukemia at ASH 2017

David Wanner,Michael Steurer

Memo – Magazine of European Medical Oncology（2018）

Cited 0|Views22
No score
Abstract
Summary At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia.
More
Translated text
Key words
Chronic lymphocytic leukemia, Ibrutinib, Venetoclax, ASH
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined